Drug Profile
Insulin oral sublingual - Albireo Pharma
Alternative Names: VIAtabLatest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator Biodel
- Developer Albireo Pharma
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 02 Mar 2023 Albireo Pharma has been acquired by Ipsen
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in USA (Sublingual, Tablet)
- 03 Feb 2011 Biodel announces its decision to limit funding to its early stage development programmes, including a sublingual insulin formulation